The DOI matches its Crossref record; 249 of the 249 references it cites were found in a registry or an index.
Potential roles of gut microbiota and microbial metabolites in Parkinson’s disease
Abstract
Parkinson's disease (PD) is a complicated neurodegenerative disease attributed to multifactorial changes. However, its pathological mechanism remains undetermined. Accumulating evidence has revealed the emerging functions of gut microbiota and microbial metabolites, which can affect both the enteric nervous system and the central nervous system via the microbiota-gut-brain axis. Accordingly, intestinal dysbiosis might be closely associated with PD. This review explores alterations to gut microbiota, correlations with clinical manifestations of PD, and briefly probes the underlying mechanisms. Next, the highly controversial roles of microbial metabolites including short-chain fatty acids (SCFAs), H 2 and H 2 S are discussed. Finally, the pros and cons of the current treatments for PD, including those targeting microbiota, are assessed. Advancements in research techniques, further studies on levels of specific strains and longitudinal prospective clinical trials are urgently needed for the identification of early diagnostic markers and the development of novel therapeutic approaches for PD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pathological changes in microbial taxonomy have been observed among PD patients.”
From Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinson’s Disease (2023) · cites this paper as [11]
In the citing paper
“the abundance of Akkermansia, Lactobacillus, and Bacteroides genera increased in PD patients, while that of Prevotella, Faecalibacterium, and Roseburia decreased remarkably [8,9,10,11].”
From Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinson’s Disease (2023) · cites this paper as [11]
In the citing paper
“the abundance of Akkermansia, Lactobacillus, and Bacteroides genera increased in PD patients, while that of Prevotella, Faecalibacterium, and Roseburia decreased remarkably [8,9,10,11].”
From Neuroprotective Effects of Sodium Butyrate by Restoring Gut Microbiota and Inhibiting TLR4 Signaling in Mice with MPTP-Induced Parkinson’s Disease (2023) · cites this paper as [11]
Citations
Cites
3 retracted
Items 201–249 of 249
Neuroprotective Effects of Molecular Hydrogen: A Critical Review
Chen, W., Zhang, H., & Qin, S.-C. (2020) · Neuroscience Bulletin · doi:10.1007/s12264-020-00597-1 · Cited by 76
Kumar, R., Yi, N., Zhi, D., Eipers, P. G., Goldsmith, K. T., Dixon, P. B., Crossman, D. K., Crowley, M. R., Lefkowitz, E. J., Rodriguez, J. M., et al. (2017) · npj Biofilms and Microbiomes · doi:10.1038/s41522-017-0020-7 · Cited by 72
Caggiu, E., Paulus, K. S., Arru, G., Piredda, R., Sechi, G., & Sechi, L. A. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.01.007 · Cited by 69
Cantu-Jungles, T. M., Ruthes, A. C., El-Hindawy, M., Moreno, R. B., Zhang, X., Cordeiro, L. M. C., Hamaker, B. R., & Iacomini, M. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.12.020 · Cited by 69
Gut microbiota, dysbiosis and colon lavage
Drago, L., Casini, V., & Pace, F. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.06.012 · Cited by 67
Alpha-synuclein immunopositive aggregates in the myenteric plexus of the aging Fischer 344 rat
Phillips, R. J., Walter, G. C., Ringer, B. E., Higgs, K. M., & Powley, T. L. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.025 · Cited by 66
Lactulose: Patient- and dose-dependent prebiotic properties in humans
Ruszkowski, J., & Witkowski, J. M. (2019) · Anaerobe · doi:10.1016/j.anaerobe.2019.06.002 · Cited by 64
Oral ‘hydrogen water’ induces neuroprotective ghrelin secretion in mice
Matsumoto, A., Yamafuji, M., Tachibana, T., Nakabeppu, Y., Noda, M., & Nakaya, H. (2013) · Scientific Reports · doi:10.1038/srep03273 · Cited by 63
Yang, H., Liu, Y., Cai, R., Li, Y., & Gu, B. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-1365 · Cited by 58
Toward the discovery and development of effective modulators of α-synuclein amyloid aggregation
Oliveri, V. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.045 · Cited by 58
Liu, M., Xie, W., Wan, X., & Deng, T. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9138 · Cited by 58
The Progressive Supranuclear Palsy Clinical Deficits Scale
Piot, I., Schweyer, K., Respondek, G., Stamelou, M., DescribePSP study group, ProPSP study group, MDS‐endorsed PSP study group, Sckopke, P., Schenk, T., Goetz, C. G., et al. (2020) · Movement Disorders · doi:10.1002/mds.27964 · Cited by 57
Wang, L., Cai, X., Shi, M., Xue, L., Kuang, S., Xu, R., Qi, W., Li, Y., Ma, X., Zhang, R., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112385 · Cited by 57
Self-citationJoers, V., Masilamoni, G., Kempf, D., Weiss, A. R., Rotterman, T. M., Murray, B., Yalcin-Cakmakli, G., Voll, R. J., Goodman, M. M., Howell, L., et al. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105027 · Cited by 56
Sharma, S., Awasthi, A., & Singh, S. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134516 · Cited by 55
Acquired dysregulation of dopamine homeostasis reproduces features of Parkinson’s disease
Bucher, M. L., Barrett, C. W., Moon, C., Mortimer, A. D., Burton, E. A., Greenamyre, J. T., & Hastings, T. G. (2020) · npj Parkinson s Disease · doi:10.1038/s41531-020-00134-x · Cited by 55
Meksawan, K., Chaotrakul, C., Leeaphorn, N., Gonlchanvit, S., Eiam-Ong, S., & Kanjanabuch, T. (2016) · Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis · doi:10.3747/pdi.2014.00015 · Cited by 54
Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease
Caggiu, E., Paulus, K. S., Galleri, G., Arru, G., Manetti, R., Sechi, G., & Sechi, L. A. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.06.004 · Cited by 53
Bacterial Metabolites Mirror Altered Gut Microbiota Composition in Patients with Parkinson’s Disease
van Kessel, S. P., & Aidy, S. E. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191780 · Cited by 53
Zhong, H., Yu, H., Chen, J., Sun, J. Y., Guo, L., Huang, P., & Zhong, Y. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00702 · Cited by 51
Inhalation of hydrogen gas elevates urinary 8-hydroxy-2′-deoxyguanine in Parkinson’s disease
Hirayama, M., Ito, M., Minato, T., Yoritaka, A., LeBaron, T. W., & Ohno, K. (2018) · Medical Gas Research · doi:10.4103/2045-9912.248264 · Cited by 50
Acylated Ghrelin as a Multi-Targeted Therapy for Alzheimer's and Parkinson's Disease
Reich, N., & Hölscher, C. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.614828 · Cited by 48
Ostendorf, F., Metzdorf, J., Gold, R., Haghikia, A., & Tönges, L. (2020) · Molecules · doi:10.3390/molecules25112502 · Cited by 46
Microbial treatment: the potential application for Parkinson’s disease
Fang, X. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3641-6 · Cited by 45
Hydrogen sulfide in longevity and pathologies: Inconsistency is malodorous
Sokolov, A. S., Nekrasov, P. V., Shaposhnikov, M. V., & Moskalev, A. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101262 · Cited by 42
Prion-Like Domains in Phagobiota
Tetz, G. V., & Tetz, V. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.02239 · Cited by 41
Regulation of immune-driven pathogenesis in Parkinson’s disease by gut microbiota
Zheng, W., He, R., Yan, Z., Huang, Y., Huang, W., Cai, Z., Su, Y., Liu, S., Deng, Y., Wang, Q., et al. (2020) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2020.01.009 · Cited by 40
Protective effect of hydrogen sulfide on oxidative stress-induced neurodegenerative diseases
Jeong, N., Jung, J., & Tabassum, R. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.265543 · Cited by 40
The GI microbiome and its role in Chronic Fatigue Syndrome: A summary of bacteriotherapy
Borody, T. J., Nowak, A., & Finlayson, S. (2012) · Journal of the Australasian College of Nutritional and Environmental Medicine · Cited by 39
Mańkowska-Wierzbicka, D., Stelmach-Mardas, M., Gabryel, M., Tomczak, H., Skrzypczak-Zielińska, M., Zakerska-Banaszak, O., Sowińska, A., Mahadea, D., Baturo, A., Wolko, Ł., et al. (2020) · Biomedicines · doi:10.3390/biomedicines8080268 · Cited by 39
Hydrogen sulfide in stroke: Protective or deleterious?
Chan, S. J., & Wong, P. T. ‐. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2016.11.015 · Cited by 38
Treatment of Nonmotor Symptoms Associated with Parkinson Disease
Goldman, J. G., & Guerra, C. M. (2020) · Neurologic Clinics · doi:10.1016/j.ncl.2019.12.003 · Cited by 36
Yamasaki, T. R., Ono, K., Ho, L., & Pasinetti, G. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00398 · Cited by 34
Liu, L., Wang, J., & Wang, H. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03801-y · Cited by 33
The Gut Mycobiome in Parkinson’s Disease
Cirstea, M. S., Sundvick, K., Golz, E., Yu, A. C., Boutin, R. C. T., Kliger, D., Finlay, B. B., & Appel‐Cresswell, S. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-202237 · Cited by 31
Chen, C., Yen, C.-Y., Chen, W.-L., Lin, C., Wu, Y., Chang, K., & Lee‐Chen, G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031062 · Cited by 31
Regulatory role of monoamine neurotransmitters in Saccharomyces cerevisiae cells
Malikina, K. D., Shishov, V. A., Chuvelev, D. I., Кудрин, В. С., & Oleskin, A. V. (2010) · Applied Biochemistry and Microbiology · doi:10.1134/s0003683810060104 · Cited by 29
Anticholinergics May Carry Significant Cognitive and Gait Burden in Parkinson's Disease
Rajan, R., Saini, A., Verma, B., Choudhary, N., Gupta, A., Vishnu, V. Y., Bhatia, R., Singh, M. B., Srivastava, A. K., & Srivastava, M. V. P. (2020) · Movement Disorders Clinical Practice · doi:10.1002/mdc3.13032 · Cited by 29
Synucleinphagy: a microglial “community cleanup program” for neuroprotection
Choi, I., Seegobin, S. P., Liang, D., & Yue, Z. (2020) · Autophagy · doi:10.1080/15548627.2020.1774149 · Cited by 26
Mariani, E., Lombardini, L., Facchin, F., Pizzetti, F., Frabetti, F., Tarozzi, A., & Casadei, R. (2018) · Genes · doi:10.3390/genes9060275 · Cited by 25
Saito, H., Nakakita, Y., Segawa, S., & Tsuchiya, Y. (2019) · Beneficial Microbes · doi:10.3920/bm2018.0091 · Cited by 21
Yshii, L., Denadai‐Souza, A., Vasconcelos, A. R., Avellar, M. C. W., & Scavone, C. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-015-0412-7 · Cited by 17
Parkinsonism in essential tremor cases: A clinicopathological study
Rajput, A. H., Rajput, E. F., Bocking, S. M., Auer, R. N., & Rajput, A. H. (2019) · Movement Disorders · doi:10.1002/mds.27729 · Cited by 16
Caballero‐Villarraso, J., Jiménez-Jiménez, M. J., Escribano, B. M., Agüera, E., Santamarı́a, A., & Túnez, I. (2019) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527318666190703102330 · Cited by 12
Barberio, B., Facchin, S., Mele, E., Renata D'Incà, Sturniolo, G. C., Farinati, F., Zingone, F., Quagliariello, A., Ghisa, M., Massimi, D., et al. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820934315 · Cited by 10
Epigenetic Study of Parkinson's Disease in Experimental Animal Model
Salama, A. F., Ibrahim, W., Tousson, E., Sakr, S. A., Masoud, A., Akela, M. A., & El-Rahman, M. A. A. (2015) · Clinical and experimental neurology · doi:10.12691/ijcen-3-1-3 · Cited by 9
Gastrointestinal Care of the Parkinson Patient
Legge, J., Fleming, N., & Cloud, L. J. (2019) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.09.003 · Cited by 8
Intrepidly studying deep brain stimulation in patients with Parkinson's disease
Deuschl, G., & Krack, P. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30138-1 · Cited by 6
Epigenetic Study of Parkinson's Disease in Experimental Animal Model
Tousson, E., Salama, A. F., Ibrahim, W., Sakr, S. A., Masoud, A., Akela, M. A., & El-Rahman, M. A. A. (2015) · Pharmacologia · doi:10.5567/pharmacologia.2015.52.62 · Cited by 6
Flagged first, then by citations
Research works printed but not linked: 2
- Travagli, 2020, Parkinson disease and the gut: new insights into pathogenesis and clinical relevance. Nature reviews, Gastroenterol. Hepatol.
- Uyar, 2019, Bioscience of microbiota, Food and Health, 38, 115
Cited by
Sorted by citations
Eicher, T. P., & Mohajeri, M. H. (2022) · Nutrients · doi:10.3390/nu14132661 · Cited by 151
Borrego-Ruiz, A., & Borrego, J. J. (2023) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2023.110861 · Cited by 111
Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside
Ma, Y., Li, X., Yu, J., & Wang, Y. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00404-1 · Cited by 96
Guo, T.-T., Zhang, Z., Sun, Y., Zhu, R.-Y., Wang, F.-X., Ma, L.-J., Jiang, L., & Liu, H.-D. (2023) · Nutrients · doi:10.3390/nu15040930 · Cited by 82
Self-citationDuan, W.-X., Wang, F., Liu, J., & Liu, C. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01123-9 · Cited by 91
Metadata
- Authors
- Zheng, S.-Y., Li, H.-X., Xu, R.-C., Miao, W.-T., Dai, M.-Y., Ding, S.-T., & Liu, H.-D.
- Affiliations
- Chongqing Medical University (CN)
- Corresponding author
- Liu, Han-Deng
- ORCID
- Xu, Rui-Chen
- Venue
- Ageing Research Reviews
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 69
- Pages
- 101347
- ISSN
- 1568-1637 (ISSN-L)
- OpenAlex
- W3159541917
- Cited by
- 101
- References
- 249
- Citations by year
- 2026: 9 · 2025: 28 · 2024: 23 · 2023: 23 · 2022: 17 · 2021: 1
- FWCI
- 1.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Ageing Research Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Chongqing Medical University (SRIEP202005)
- Science and Technology Planning Project of Yuzhong District of Chongqing City (20180112)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- Parkinson's disease, gut microbiota, microbial metabolites, microbiota-gut-brain axis, gut dysbiosis, short-chain fatty acids, hydrogen sulfide, hydrogen, enteric nervous system, neurodegeneration, microbiota-targeted therapy, diagnostic biomarkers
- MeSH terms
- Gastrointestinal Microbiome, Humans, Parkinson Disease, Prospective Studies, Neurodegenerative Diseases, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
